BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 16897971)

  • 21. Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002).
    Uedo N; Narahara H; Ishihara R; Takiuchi H; Goto M; Fujitani K; Hirao M; Tsujinaka T; Imano M; Furukawa H; Tsukuma H; Taguchi T
    Oncology; 2007; 73(1-2):65-71. PubMed ID: 18334851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [CPT-11 combined chemotherapy for metastatic gastric cancer].
    Narahara H; Sugimoto N; Iishi H; Tatsuta M
    Gan To Kagaku Ryoho; 2004 Nov; 31(12):1973-7. PubMed ID: 15570923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002).
    Narahara H; Iishi H; Imamura H; Tsuburaya A; Chin K; Imamoto H; Esaki T; Furukawa H; Hamada C; Sakata Y
    Gastric Cancer; 2011 Mar; 14(1):72-80. PubMed ID: 21340666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study.
    Lenz HJ; Lee FC; Haller DG; Singh D; Benson AB; Strumberg D; Yanagihara R; Yao JC; Phan AT; Ajani JA
    Cancer; 2007 Jan; 109(1):33-40. PubMed ID: 17133415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Combination chemotherapy of S-1 and CPT-11 for advanced recurrent gastric cancer].
    Akasaka O; Iwase S; Miwa H; Ando T; Morita S; Koh R; Kasama M; Matsueda R; Anan H
    Gan To Kagaku Ryoho; 2009 Nov; 36(11):1833-7. PubMed ID: 19920384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
    Hirakawa M; Sato Y; Ohnuma H; Takayama T; Sagawa T; Nobuoka T; Harada K; Miyamoto H; Sato Y; Takahashi Y; Katsuki S; Hirayama M; Takahashi M; Ono M; Maeda M; Takada K; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Hirata K; Kato J
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):789-97. PubMed ID: 23338051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule].
    Goto A
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():125-30. PubMed ID: 16897987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [TS-1/CDDP therapy for advanced gastric cancer as neoadjuvant chemotherapy].
    Nakamura M; Maruyama K; Furukawa J; Maruyama N; Tanaka J; Katsumoto Y; Yokouchi H; Nakaguchi K; Sue F; Yoshihara W
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1823-8. PubMed ID: 12402437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
    Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
    Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group.
    Koizumi W; Kurihara M; Nakano S; Hasegawa K
    Oncology; 2000 Apr; 58(3):191-7. PubMed ID: 10765119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Chemotherapy for gastric cancer].
    Baba H; Kakeji Y; Oki E; Tokunaga E; Ushiro S; Watanabe M; Maehara Y
    Gan To Kagaku Ryoho; 2003 Nov; 30(12):1881-8. PubMed ID: 14650954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
    Hironaka S; Sugimoto N; Yamaguchi K; Moriwaki T; Komatsu Y; Nishina T; Tsuji A; Nakajima TE; Gotoh M; Machida N; Bando H; Esaki T; Emi Y; Sekikawa T; Matsumoto S; Takeuchi M; Boku N; Baba H; Hyodo I
    Lancet Oncol; 2016 Jan; 17(1):99-108. PubMed ID: 26640036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma.
    Ajani JA; Lee FC; Singh DA; Haller DG; Lenz HJ; Benson AB; Yanagihara R; Phan AT; Yao JC; Strumberg D
    J Clin Oncol; 2006 Feb; 24(4):663-7. PubMed ID: 16446338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Feasibility of S-1/CDDP therapy for outpatients with advanced gastric cancer].
    Rino Y; Murakami H; Yukawa N; Wada N; Oshima T; Matsuura H; Sugano N; Arai H; Masuda M; Imada T
    Gan To Kagaku Ryoho; 2009 Nov; 36(11):1829-31. PubMed ID: 19920383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma.
    Blum M; Suzuki A; Ajani JA
    Future Oncol; 2011 Jun; 7(6):715-26. PubMed ID: 21675835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Combination chemotherapy of S-1 plus biweekly docetaxel for advanced and recurrent gastric cancer].
    Takahashi I; Oki E; Egashira A; Morita M; Kakeji Y; Maehara Y
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():87-90. PubMed ID: 16897979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer.
    Kinoshita T; Nashimoto A; Yamamura Y; Okamura T; Sasako M; Sakamoto J; Kojima H; Hiratsuka M; Arai K; Sairenji M; Fukushima N; Kimura H; Nakajima T
    Gastric Cancer; 2004; 7(2):104-9. PubMed ID: 15224197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [S-1 combined with weekly dosing of cisplatin for metastatic gastric cancer].
    Hyodo I
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():64-7. PubMed ID: 16897974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Combination therapy with S-1 and CDDP for head and neck cancer].
    Fujii M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():150-4. PubMed ID: 16897992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer.
    Komatsu Y; Yuki S; Fuse N; Kato T; Miyagishima T; Kudo M; Kunieda Y; Tateyama M; Wakahama O; Meguro T; Sakata Y; Asaka M
    Adv Ther; 2010 Jul; 27(7):483-92. PubMed ID: 20559897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.